Endocrine Cancer News
Cabozantinib prolongs progression-free survival in patients with previously treated radioiodine-refractory differentiated thyroid cancer, a phase 3 trial suggests.
Proton FLASH radiotherapy is feasible, safe, and provides pain relief for cancer patients with bone metastases, according to a first-in-human trial.
The incidence of invasive breast cancer among childhood cancer survivors decreased from the 1970s to the 1990s.
Active surveillance may be a viable management strategy for most diagnosed thyroid cancers, according to researchers.
Donafenib demonstrated efficacy in patients with progressive, locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.
177Lutetium-octreotate can improve progression-free survival vs sunitinib in patients with progressive pancreatic neuroendocrine tumors.
Etoposide plus cisplatin and irinotecan plus cisplatin remain the standard first-line chemotherapy options for advanced digestive neuroendocrine carcinoma, according to researchers.
Men tend to have a higher risk of cancer than women, and factors such as smoking, alcohol use, and diet do not appear to explain this disparity.
Many thyroid cancers are discovered in patients who undergo surgery without thyroid-referable symptoms, an international study suggests.
Blood type may influence response to immune checkpoint inhibitor therapy among patients with metastatic cancer, a study suggests.
There were more than 18 million cancer survivors in the United States at the beginning of this year, according to new data.
Bridging therapy before ASCT improved event-free survival for patients with stable metastatic disease at the end of induction.
Hispanic children had inferior overall survival despite receiving the same treatment as their peers.
Nearly 70% of patients had at least 1 potentially actionable therapeutic target.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
The risk of breakthrough SARS-CoV-2 infections was highest for liver cancer and lowest for thyroid cancer.
At the start of the pandemic, there was an immediate 34.3% decline in the estimated mean cancer incidence volume.
Radioiodine after thyroidectomy did not improve outcomes in patients with low-risk thyroid cancer.
When compared with chemotherapy or targeted therapy, peptide receptor radionuclide therapy significantly prolonged progression-free survival.
Researchers hypothesized that a rising number of thyroid cancer rates in adults with obesity in may also imply an increase in thyroid cancer rates in children.
The complete response rate was similar for patients who received selumetinib and those who received radioactive iodine alone.
The largest declines in incidence were seen for cervical, endocrine, and prostate cancers, as well as melanoma.
Elevated urinary 3MT levels were tied to worse event-free and overall survival.
Analysis of messenger RNA, microRNA, and protein-encoding genes may predict the risk of papillary thyroid cancer recurrence.
Apatinib improved progression-free survival regardless of baseline thyroglobulin levels.